Hennion & Walsh Asset Management Inc. Acquires 44,832 Shares of Altimmune, Inc. (NASDAQ:ALT)

Hennion & Walsh Asset Management Inc. grew its position in Altimmune, Inc. (NASDAQ:ALT) by 34.7% in the 3rd quarter, according to its most recent disclosure with the SEC. The fund owned 174,108 shares of the company’s stock after buying an additional 44,832 shares during the period. Hennion & Walsh Asset Management Inc. owned approximately 0.25% of Altimmune worth $1,069,000 as of its most recent SEC filing.

Several other large investors have also bought and sold shares of the company. Creative Planning raised its holdings in Altimmune by 20.5% in the third quarter. Creative Planning now owns 18,411 shares of the company’s stock worth $113,000 after buying an additional 3,132 shares during the last quarter. Exchange Traded Concepts LLC raised its holdings in Altimmune by 74.4% in the third quarter. Exchange Traded Concepts LLC now owns 216,761 shares of the company’s stock worth $1,331,000 after buying an additional 92,498 shares during the last quarter. PVG Asset Management Corp purchased a new position in Altimmune in the second quarter worth about $154,000. B. Riley Wealth Advisors Inc. purchased a new position in Altimmune in the second quarter worth about $138,000. Finally, The Manufacturers Life Insurance Company raised its holdings in Altimmune by 30.7% in the second quarter. The Manufacturers Life Insurance Company now owns 26,973 shares of the company’s stock worth $179,000 after buying an additional 6,339 shares during the last quarter. 78.05% of the stock is owned by hedge funds and other institutional investors.

Insiders Place Their Bets

In other Altimmune news, Director David Drutz sold 16,011 shares of the firm’s stock in a transaction that occurred on Monday, August 19th. The shares were sold at an average price of $6.90, for a total transaction of $110,475.90. Following the sale, the director now owns 41,958 shares in the company, valued at approximately $289,510.20. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. 4.10% of the stock is owned by company insiders.

Analysts Set New Price Targets

Several research firms have recently weighed in on ALT. Evercore ISI raised shares of Altimmune to a “strong-buy” rating in a report on Friday, August 9th. B. Riley reissued a “buy” rating and set a $20.00 price objective on shares of Altimmune in a report on Monday, August 12th. Finally, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Altimmune in a report on Thursday, August 22nd. Two analysts have rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, Altimmune presently has a consensus rating of “Moderate Buy” and an average target price of $18.80.

Altimmune Price Performance

NASDAQ:ALT opened at $6.69 on Monday. Altimmune, Inc. has a one year low of $2.24 and a one year high of $14.84. The business has a fifty day moving average price of $6.77 and a 200-day moving average price of $6.88. The firm has a market capitalization of $475.46 million, a price-to-earnings ratio of -4.13 and a beta of 0.08.

Altimmune (NASDAQ:ALT) last issued its quarterly earnings results on Thursday, August 8th. The company reported ($0.35) EPS for the quarter, missing analysts’ consensus estimates of ($0.34) by ($0.01). Altimmune had a negative return on equity of 53.09% and a negative net margin of 24,778.97%. The company had revenue of $0.01 million during the quarter. During the same period last year, the firm posted ($0.32) EPS. On average, equities research analysts expect that Altimmune, Inc. will post -0.54 earnings per share for the current fiscal year.

Altimmune Company Profile

Altimmune, Inc, a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis.